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ABSTRACT  
2-phenylethynesulfonamide (PES) or pifithrin-µ is a promising anticancer agent with 
preferential toxicity for cancer cells. The type of cell death and the molecular cascades 
activated by this compound are controversial. Here, we demonstrate PES elicits a 
caspase- and BAX/BAK-independent non-necroptotic necrotic cell death, since it is not 
inhibited by Necrostatin-1. This process is characterized by an early generation of 
reactive oxygen species (ROS) resulting in p53 up-regulation. Accordingly, thiolic 
antioxidants protect cells from PES-induced death. Furthermore, inhibiting the natural 
sources of glutathione with L-buthionine-sulfoximine (BSO) strongly cooperates with 
PES in triggering cytotoxicity. Genetically modified p53-null or p53 knocked-down cells 
show resistance to PES-driven necrosis. The predominant localization of p53 in 
chromatin-enriched fractions added to the up-regulation of the p53-responsive gene 
p21, strongly suggest the involvement of a transcription-dependent p53 program. On 
the other hand, we report an augmented production of ROS in p53-positive cells that, 
added to the increased p53 content in response to PES-elicited ROS, suggests that p53 
and ROS are mutually regulated in response to PES. In sum, p53 up-regulation by ROS 
triggers a positive feedback loop responsible of further increasing ROS production and 
reinforcing PES-driven non-necroptotic necrosis. 
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1. Introduction 
PES (2-phenylethynesulfonamide), also named pifithrin-µ, was first identified as a 
compound able to repress apoptosis induced by the translocation of p53 to the 
mitochondria [1]. Further studies have revealed that PES is an effective inducer of cell 
death with increased selectivity for cancer cells [2]. The pharmacological actions of PES 
include the blockage of both the proteasome and the autophagic process [3]. These to 
actions converge in increasing the proteotoxic stress of the highly metabolically-active 
cancer cells but, also, in inactivating proteins, such as p53, through its inclusion in 
insoluble aggregates [3]. This p53 inactivating mechanism, plus the fact that p53-
defective cells are not resistant to PES, has supported the idea of a null involvement of 
p53 in the process of cell death triggered by this molecule. Cell death, cell cycle arrest, 
senescence, DNA repair, glucose metabolism, ROS generation and autophagy are 
some of the cellular phenomena regulated by p53 [4]. p53 is the most frequently 
mutated tumor suppressor gene in human cancer [5,6]. Most cellular insults trigger 
intracellular signaling cascades that converge in p53 activation, for example DNA 
damage, viral infection, oncogene activation or ROS generation [4,7]. In response to 
these stimuli, p53 is stabilized and engages a plethora of molecular pathways, including 
both transcriptional and non-transcriptional events [4,8].  
Necrotic cell death was initially described as a passive mechanism of cell 
demise. For a while, necrosis became synonym of accidental death and was defined by 
its morphological traits [9]. However, further research uncovered necrosis as a 
regulated process in many instances [10,11]. Necroptosis is a type of regulated necrosis 
mediated by the activation of receptor-interacting protein kinase 1 (RIPK1) and RIPK3. 
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Necrostatin-1 is a RIPK1 inhibitory drug, which allows the inhibition and identification of 
necroptotic cell death [12]. 
We set out to gain a better understanding of how PES kills cancer cells. PES 
elicited a non-apoptotic, non-autophagic, non-necroptotic cell death in SH-SY5Y and 
HCT116 cells. Interestingly, PES triggered an early burst on ROS content, which was 
required for cytotoxicity. We observed a ROS-dependent increase in the p53 protein 
levels, mostly located at the chromatin-enriched fraction and followed by an increase on 
p21 content. p53 up-regulation boosted cell sensitivity to PES-mediated necrosis. In this 
sense, silencing p53 diminished the cytotoxic response to PES. In sum, our results 
indicate that ROS produced by PES trigger the up-regulation of p53, which, in turn, 
increases the production of ROS, resulting in a non-necroptotic form of necrosis. 
 
 
2. Material and Methods 
 
 
2.1 Cell culture and drug treatments 
Colon adenocarcinoma HCT116 and HCT116 p53-/- cells were obtained from Dr. 
Vogelstein’s laboratory [13]. The immortalized MEF Bax-/-Bak-/- and their WT 
counterparts were obtained from Dr. Korsmeyer’s laboratory [14,15]. SH-SY5Y, 
HEK293, U87MG, HeLa and HL-60 cell lines were obtained from the American Type 
Culture Collection. SH-SY5Y, HEK293, U87MG, HeLa and MEFs were maintained in 
DMEM, HL-60 in RPMI and all the colon-derived cells in McCoy’s media. All media were 
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supplied by Lonza (Rockland, ME, USA) and supplemented with 10% FCS (Gibco part 
of Invitrogen, Paisley, UK). PlasmocinTM (InvivoGen, San Diego, CA, USA) at 5 µg/ml 
final concentration was added as a prophylactic antibiotic. Cultures were regularly PCR-
tested to confirm mycoplasma-free conditions. Cultures were maintained at 37ºC in 
water-saturated, 5% CO2 atmosphere. Stock solutions of PES and the other chemicals 
were prepared in DMSO. From these stock solutions, drugs were delivered to the 
culture media and adjusted to the final concentrations reported in the text and figures. 
The serial dilution procedure was used in concentration-dependency determinations. 
 
 
2.2 Chemical reagents 
CellTiter 96® kit containing the reagent MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxy-methoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was provided by Promega 
(Madison, WI, USA). Pierce Biotechnology (Rockford, IL, USA) provided Alamar blueTM 
Cell Viability Assay Reagent. Q-VD-OPh (Q-Val-Asp(non-methylated)-OPh) and 3-
methyladenine (3-MA) were obtained from Calbiochem part of Merck KGaA (Darmstadt, 
Germany). AcDEVDafc (Acetyl-Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl-coumarin) 
was purchased from Enzo Life Sciences (Farmingdale, NY, USA). Dithiothreitol (DTT) 
was from Thermo Fisher Scientific (Waltham, MA, USA). Necrostatin-1 was purchased 
from Tocris Bioscience (Ellisville, MI, USA). Staurosporine (STS), Spautin-1, 
bisBenzimide (Hoechst 33342), PI (Propidium iodide), N-acetyl-L-cysteine (NAC) and L-
buthionine-sulfoximine (BSO) were supplied by Sigma-Aldrich (St. Louis, MO, USA).  
Unless otherwise stated, the non-listed reagents were also from Sigma. 
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2.3 Cell survival and cell death and nuclear morphology assessment 
To determine cell survival, MTS or Alamar blue reagents were used indistinctly. 
Both assays couple a nonspecific cellular reductase activity of viable cells to the 
reduction of a dye into colored (MTS) or fluorescent (Alamar blue) products, which are 
subsequently quantified. Percentage of viability was obtained by referring these values 
to the ones obtained with a population of vehicle treated cells. To assess cell death, 
cultures stained with PI, were trypsinized and subjected to flow cytometry analysis. 
Nuclear morphology was observed by direct fluorescence microscopy of cells in media 
containing 0.05 µg/ml bisBenzimide plus 12.5 µg/ml PI as previously described [11].  
 
 
2.4 Caspase activity 
Effector caspase activation (DEVDase activity) was obtained by quantifying the 
fluorescence released from Ac-DEVD-afc substrate after incubation at 37°C in the lysed 
cell cultures. This method has been validated and described in our previous work [16]. 
 
 
2.5 Overexpression of p53 
HCT116 p53-/- cells, plated at 1.2 x 106 in p35 wells, were transfected with 6 µg 
of pCMV-Neo-Bam p53 WT or pCMV-Neo-Bam [17] in combination with 0.6 µg of a 
plasmid containing GFP. DNA was prepared in Opti-MEMTM media (Life Technologies, 
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Carlsbad, CA, USA) before adding Turbofect transfection reagent (Thermo Fisher 
Scientific, Waltham, MA, USA) as described in the instructions manual. After 24 h, cells 
transfected were plated in M96 plates for drug treatment and cell viability assessment. 
 
 
2.6 Lentiviral production and infection 
FSV and FSV p53 lentiviral constructs were gently provided by Dr. Xavier Dolcet 
and Dr. Núria Eritja.  Vectors contained a U6 promoter for expression of short hairpin 
RNAs against p53 (GTCCAGATGAAGCTCCCAGAA) and the Venus variant of YFP 
under the control of an SV40 promoter for monitoring transduction efficiency. Lentiviral 
particles were produced in 293T cells co-transfected by the calcium phosphate method 
with the above plasmid plus plasmids coding for the envelope and the packaging 
systems (VSV-G and ∆8.9, respectively). The day after transfection, 293T cells were 
switched to media containing no anti-mitotics and left for 2–3 days. Supernatants were 
then harvested, filtered through a 0.45 µm filter, and directly added to cultures in the 
presence of Polybrene (Merck Millipore part of Merck KGaA, Darmstadt, Germany). 
 
 
2.7 Electron microscopy 
Cells were collected, washed twice in PBS (150 mM ClNa, 2.7 mM ClK, 8 mM 
Na2HPO4, 1.5 mM KH2PO4) and fixed for 30 min at 4 °C in 100 mM phosphate buffer 
(pH 7.4) containing 2.5% glutaraldehyde. After rinsing the pellets twice with PBS at 
4 °C, the cells were post-fixed in buffered OsO4, dehydrated in graded acetone and 
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embedded in Durcupan® ACM resin (Sigma-Aldrich, St. Louis, MI, USA). Ultrathin 
sections mounted on copper grids were counterstained with uranyl acetate and lead 
citrate. A transmission electron microscope (Zeiss EM 910) was employed to visualize 
the cellular ultrastructure. 
 
 
2.8 Intracellular ROS measurement 
The quantification of intracellular ROS was based on fluorescence of the 
compound DCF that results from cell metabolization and ROS action on the precursor 
compound 2’,7’dichlorofluorescin diacetate. Briefly, cells were seeded in 96 well plates.  
Media was replaced 48 h later by Phenol-red free Hank’s Balanced Salt Solution 
containing 10 µM DCF. After an incubation of 30 min, the reagent was removed and 
cells were washed with pre-warmed PBS. Cultures were then immediately incubated in 
full media containing the investigated drug. At the times desired, fluorescence was read 
at 485/530 nm (excitation/emission wavelengths) with a plate reader (Infinite® M200, 
Tecan, Maennedorf, Switzerland). 
 
 
2.9 Protein extraction and Western blotting 
To perform whole cell extracts, cells were lysed in a buffer containing 100 mM 
Tris/ClH pH 6.8, 1% SDS, 1 µM EDTA, plus the cocktail of protease inhibitors from 
Sigma followed by sonication. After a centrifugation at 12,000 × g for 15 min, a total 
protein extract was obtained. To obtain extracts from specific cell subfractions 
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(cytosolic, nucleoplasmic and chromatin-enriched), we followed the protocol described 
in a previous publication [18]. The protein concentration was determined by means of 
the DC Protein Assay (BioRad, Hercules, CA, USA). Volumes were calculated to 
equalize the protein load in SDS 12%-polyacrylamide gel electrophoresis. Following 
electrotransfer to 0.45 µm PVDF membranes (EMD Millipore part of Merck KGaA, 
Darmstadt, Germany), we applied the following antibodies: anti-p53 clone BP53-12 
(Upstate, part of Merck KGaA, Darmstadt, Germany), anti-p21 clone CP74 (Sigma, St. 
Louis, MI, USA), anti-lactate dehydrogenase (LDH) (RocklandTM Immunochemicals Inc., 
Boyertown, PA, USA), anti-polypyrimidine tract binding protein 1 (PTBP1) ab5642 
(Abcam, Cambridge, England, UK) and anti-GAPDH-Peroxidase clone GAPDH-71.1 
(Sigma, St. Louis, MI, USA). Immunoblots were finally developed with the ImmobilonTM 
reagent from Millipore part of Merck KGaA (Darmstadt, Germany). Chemiluminiscence 
was recorded and densitometric analysis was performed by means of a ChemidocTM 
apparatus and the Image Lab version 4.0.1 software from Bio-Rad. To quantify 
expression of p53, values of signal intensity were normalized to the appropriate signal in 
control extracts. Alternatively, to quantify p53 or p21 content in Fig. 6B or Fig. 7A, 
values of signal intensity were first referred to the values of GAPDH and then, 
normalized to a non-induced condition. 
 
 
3. Results 
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3.1 PES triggers caspase-independent non-apoptotic cell death 
 A panel of human-derived cell lines (SH-SY5Y from neuroblastoma, U87MG from 
grade III astrocytoma, HL-60 from acute promyelocytic leukemia, HEK293 from 
embryonic kidney, HeLa from cervical cancer, and HCT116 from colorectal carcinoma) 
was used to assay the cytotoxicity induced by increasing concentrations of PES. As 
shown in Fig. 1A, PES triggered loss of cell viability in a concentration-dependent 
manner. In support of previous observations, the non-tumor derived HEK293 cells 
displayed a greater resistance to PES-driven toxicity [2]. We focused our research on 
HCT116 and SH-SY5Y, two tumor-derived cell lines with different ontogeny, being SH-
SY5Y neatly more sensitive to PES than HCT116. Plasmatic membrane rupture by 
means of PI permeability was evaluated over time at concentrations of 12.5 and 25 µM 
PES in SH-SY5Y and HCT116, respectively. As shown in Figs. 1, B and C, 12.5 µM 
PES for 24 h in SH-SY5Y was equivalent to 25 µM for 48 h in HCT116. At these 
concentrations, 60% of SH-SY5Y and HCT116 cells were PI positive after 24 h and 48h, 
respectively. To assess whether the type of cell death was apoptotic, we double stained 
nuclei with bisBenzimide and Propidium iodide (PI). In these experiments, HCT116 and 
SH-SY5Y did not present evident chromatin condensation or nuclear fragmentation, 
which are distinctive traits of apoptosis. A similar behavior was observed in U87MG, 
HeLa, 293HEK and HL-60 cells when assaying concentrations of PES that at 24 h 
triggered death in 50% of the cell populations (results not shown). To sustain the 
absence of apoptotic death in HCT116 and SH-SY5Y, caspase activation (DEVDase 
activity) was evaluated through time. As expected, PES was unable to trigger caspase 
activation in both cell lines (Figs. 2A and B). As a control, we assessed caspase activity 
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in response to Staurosporine (STS), thus confirming the caspase functionality in both 
cell lines (Figs. 2A and B). Equivalent results were obtained when applying the same 
strategy to U87MG, HeLa, 293HEK and HL-60 cells (Fig. 2C). To further discard 
apoptosis as the predominant death process engaged by PES, we tested its effects on 
mouse embryonic fibroblasts (MEFs) defective in both, BAX and BAK. These proteins 
are key positive mediators at the mitochondrial or intrinsic pathway of apoptosis and, 
therefore, MEF Bax-/-Bak-/- cells become completely unresponsive to the stimuli that 
trigger it. As expected, MEF Bax-/-Bak-/- cells displayed resistance to STS as compared 
to their WT counterparts. However, deficiency of BAX and BAK provided no protection 
when cells were treated with PES (Fig. 2D). Altogether these results indicated that PES 
was triggering caspase- and BAX/BAK-independent cell death in HCT116 and SH-
SY5Y cells and suggested the involvement of a necrotic type of cellular demise. 
 
 
3.2 PES induces a non-necroptotic, necrotic type of cell death 
Depending on the cellular model, PES either elicits caspase-independent [2,19] 
or caspase-dependent [20–22] cell death, or a mixture of both [23]. To gain insight on 
the kind of cell death induced by PES, we evaluated the protective effects of commonly 
used inhibitors of death. Blockage of either apoptosis with the broad caspase inhibitor 
Q-VD-OPh, necroptosis with RIPK1 inhibitor Necrostatin-1 or autophagy-driven cell 
death with 3-MA or Spautin-1, proved to be inefficient strategies to avoid PES-triggered 
cell death (Fig. 3A). Morphological studies by electronic microscopy remain one of the 
best methods to ascertain necrosis [9]. HCT116 cells displayed a morphological 
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phenotype consistent with its origin in colon epithelia, with cells establishing junctions at 
the contact sites and displaying mitochondria and Golgi apparatus in a polarized way at 
a side of the nucleus (Fig. 3B). Upon PES treatment, HCT116 cells underwent 
mitochondrial disruption and an increased cytoplasm vacuolization (Fig. 3C). Later in 
the process, cell membrane became ruptured and the cytoplasm severely unstructured 
(Fig. 3D). These traits were consistent with a necrotic type of cell death. Similar 
morphological changes were observed in PES-challenged SH-SY5Y cells, with images 
of severely disrupted mitochondria only after 12 h of treatment (Fig. 3F). Together, 
these results indicated PES triggered a non-necroptotic, necrotic type of cell death. 
 
 
3.3 ROS are pivotal elements in necrosis driven by PES 
When the intracellular antioxidant systems are overloaded, the excess of ROS 
leads to oxidative stress, to the damage of essential biological components and, 
eventually, to necrosis [9]. In an attempt to establish a potential link between PES-
driven necrosis and oxidative stress, we monitored the induction of ROS by PES in a 
time-dependent manner. At merely 30 min of PES treatment, we detected a significant 
increase in ROS content (Fig. 4A). To evaluate the relevance of the observed ROS in 
PES-driven necrosis, we assessed the effects of thiolic antioxidants, such as 
dithiothreitol (DTT) and N-Acetyl Cysteine (NAC) and confirmed they conferred a 
significant protection to PES-mediated necrosis in both SH-SY5Y and HCT116 cells 
(Figs. 4B and C). Efficient suppression of ROS by either DTT or NAC in combination 
with PES was controlled and confirmed by ROS quantification (data not shown). These 
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findings were consistent with necrosis being a consequence of ROS build-up in 
response to PES. To further validate the central role of ROS in PES-induced necrosis, 
HCT116 and SH-SY5Y cells were challenged with combinations of PES and L-
Buthionine sulphoximine (BSO). BSO is a specific inhibitor of γ-glutamylcysteine 
synthetase able to deplete the intracellular levels of glutathione [24,25]. BSO and the 
subsequent glutathione depletion are not toxic for most cells unless subjected to 
oxidative stress [26]. Therefore, HCT116 and SH-SY5Y cells were pre-incubated with 
BSO and exposed to sublethal concentrations of PES. Under these circumstances, we 
reported a significant increase of ROS content (Fig. 4D). Thus supporting BSO 
improves generation of ROS by PES. Next, we applied this combination to our 
experimental paradigms and assessed the impact on their survival. Accordingly, BSO 
strongly cooperated with sublethal concentrations of PES to trigger cell death in 
HCT116 and SH-SY5Y cells (Fig. 4E). This cooperation was also detected in other cell 
lines, for instance U87MG and HeLa cells, which were more resistant to PES-deadly 
actions (Fig. 1A). Together, these findings reinforced the involvement of ROS in PES-
triggered necrosis. 
 
 
3.4 p53 participates in PES-driven necrosis 
p53 is a pivotal stress sensor that responds to a great variety of cell insults by 
orchestrating cell demise. Besides apoptosis and autophagic cell death, p53 is also 
involved in necrosis [27–29]. To ascertain the involvement of p53 in PES-triggered 
necrosis, we used HCT116 cells and their p53-deficient counterparts. HCT116 p53-/- 
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cells required higher concentrations of PES to get the same amount of cell death found 
in HCT116 cells, after 24 h of treatment (Fig. 5A). Indeed, leakage of the membrane in 
HCT116 p53-/- cells was significantly protected (15.6±8.1 % of PI-positive cells) when 
compared to HCT116 (45.5±7.7 % of PI-positive cells) (Fig. 5B). To better demonstrate 
the observed differences were due to p53 and not to unrelated phenomena, we 
reintroduced a functional p53 into HCT116 p53-/- cells. Transient transfection of p53 
sensitized HCT116 p53-/- cells to PES-driven cell death (Fig. 5C). These data were in 
agreement with p53 being implicated in PES-driven necrosis.  
 
 
3.5 p53 is predominantly located at the chromatin-enriched cellular fractions in 
response to PES  
Since PES blocks the transcription-independent p53 translocation to 
mitochondria [1], we surmised the observed p53-dependent susceptibility could rely on 
its transcriptional activity, which consists in the regulation of a specific set of genes by 
binding to p53-responsive elements [30]. To do so, p53 needs to be located at the 
nucleus, more precisely at the chromatin-enriched fraction. Therefore, direct proof of 
this localization was necessary to substantiate p53 was modulating transcription of 
target genes. To experimentally find this evidence, we first interrogated the presence of 
p53 in chromatin-enriched fractions after challenging cells with PES. Using a previously 
described method to precisely separate cellular extracts into specific fractions [18], SH-
SY5Y extracts were subfractionated into a cytoplasmic fraction, enriched in 0.1% triton-
soluble proteins (C) and two nuclear fractions, one enriched in hydrosoluble proteins or 
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nucleoplasm (N1) and the other, containing the insoluble and chromatin-bound proteins 
(N2). In healthy non-treated SH-SY5Y cells, most of the p53 content was found in either 
nucleoplasmic- or chromatin-enriched fractions. However, after PES treatment, p53 was 
preferentially found in the chromatin-enriched fraction (Fig. 6A). Precisely, p53 
surpassed the control by 3 folds in the nucleoplasmic fraction and 6 folds in the 
chromatinic one (Fig. 6A). Purity of the fractions was controlled by the presence of the 
cytoplasmic enzyme lactate dehydrogenase (LDH) and nuclear polypyrimidine tract 
binding protein 1 (PTBP1). These data supported that PES was up-regulating p53, 
which located at the nucleus, where probably it was triggering the transcription of p53-
responsive genes involved in a form of oxidative stress-regulated necrotic cell death. To 
validate this up-regulation in a time-dependent manner, total levels of p53 in SH-SY5Y 
cells were studied over a 24 h period of treatment. A notable increase of p53 content 
was evident at 6 h, before any sign of necrosis occurred (aprox. 2.4 folds over time 0, 
Fig. 6B). In parallel, abundance of one of the best-known transcriptional targets of p53, 
p21 [31,32], was monitored. Kinetics of p21 paralleled those of p53 (Fig 6B). Similar 
results were obtained with HCT116 cells (not shown). Overall, these results were 
suggestive of a functional p53, activating transcription in response to PES. Finally, we 
considered that specific inhibition of p53 would be of paramount importance to assess 
its role in cell death. To do so, endogenous p53 was specifically silenced with a 
lentivirus carrying an shRNA against p53 (shp53). We observed an increase in the 
resistance of HCT116 (Fig. 6C) and SH-SY5Y (Fig. 6D) cells to PES-induced necrosis 
in any of the concentrations employed. Efficiency of p53 down-regulation was assessed 
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and found to be greater than 80% by Western-blot (data not shown). Therefore, we 
concluded that a p53-dependent program was involved in necrosis triggered by PES.  
 
 
3.6 ROS and p53 form a positive feedback loop in PES-mediated necrosis 
p53 can either be activated in response to oxidative stress or, alternatively, 
generate ROS through transcription-dependent mechanisms [7]. Several experiments 
were performed to distinguish between these two possibilities. First, SH-SY5Y cells 
were either treated with PES plus or minus DTT and p53 content was assessed by 
Western-blot (Fig. 7A). Cells challenged with PES up-regulated p53 by 35 folds 
compared with untreated cells. Although single DTT treatment increased p53 by 10 
folds, combination of DTT and PES resulted in a 15 folds increase. In other words, in 
the presence of DTT, PES triggered a mere increase of 1.5 folds over DTT, indicating 
that p53 up-regulation was mainly a response to the generation of ROS. Second, we 
evaluated the production of ROS in p53-null cells stimulated with PES. At times when 
p53 was up-regulated by PES, HCT116 p53 -/- cells generated significantly lower 
amounts of ROS than HCT116 cells (Fig. 7B). In sum, we showed ROS up-regulated 
p53 and p53 promoted ROS generation. Therefore we propose the existence of a 
positive feed back loop between p53 and ROS in the process of PES-mediated 
necrosis.  
 
 
4. Discussion 
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Here, we describe PES induces cytotoxicity in cell lines of different ontogeny. 
Cell death by this compound is caspase-independent and presents a prominent 
cytoplasmic vacuolization. The nuclei of PES-injured cells do not show morphological 
traits of apoptotic cell death. Moreover, PES promotes an early induction on the 
intracellular ROS content that, in turn, is a key event for the cytotoxic process. This 
oxidative stress is responsible of an up-regulation of p53, which participates in PES-
driven cell death. Notably, down-regulation or genetic suppression of p53 makes cells 
more resistant to necrosis induced by PES. Localization of p53 in the chromatin-bound 
fraction and up-regulation of p21 indicate the involvement of a transcription-dependent 
p53 program in PES-driven necrosis. Finally, we also present evidence of PES eliciting 
a positive feedback loop between ROS and p53, which results in the final necrotic 
outcome. 
p53, also known as the “guardian of the genome”, is a pivotal element in the cell 
response to chemotherapeutic agents. The fact that p53-defective cells remain sensitive 
to PES-induced cell death is taken as a proof of its irrelevance in the process [2,21]. 
Nonetheless, up-regulation of p53 in response to PES is reported in multiple cell lines 
[2,3]. There exists only one exception in which PES triggers p53-independent apoptosis, 
without p53 up-regulation [21]. Under these premises, we interrogated the involvement 
of p53 in genetically modified experimental paradigms: HCT116 and their isogenic 
HCT116 p53-/-, HCT116 p53-/- cells overexpressing a functional p53, and, finally, 
HCT116 and SH-SY5Y cells with diminished levels of p53. Regardless of the genetically 
modified paradigm, p53 exerted a positive role, increasing PES-triggered necrosis. 
Moreover, we have provided evidences of p53 transcriptional involvement since p53 
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remains in the appropriate nuclear compartment for transcription modulation and 
content of p21 is increased. 
Blockade of RNA polymerase II-mediated transcription induces p53 accumulation 
in mitochondria, being the critical factor for eliciting p53-dependent, but transcription-
independent, apoptosis [33].  On the contrary, PES is a well-known inhibitor of p53 
translocation to mitochondria [1] with no reported effects on transcription. Applying the 
former reasoning, PES-driven global increase of p53, having its movement to the 
mitochondria impeded, could act as a permissive event for p53 transcription-dependent 
necrosis to occur. Despite our findings, high concentrations of PES are cytotoxic in 
HCT116 p53-/- cells. Our explanation to this phenomenon is the loss of drug specificity 
at the highest concentrations employed. Our data also evidence that PES triggers cell 
death in p53-null cells, such as HL-60. In this regard, when high concentrations of PES 
are used, we cannot rule out the involvement of other members of the p53 family of 
transcription factors, such as p63 or p73, which all share amino acid sequence identity 
in the DNA-binding domain, and thus could present redundant functions in the 
regulation of gene expression [34]. 
The critical role of ROS in the regulation of necrotic pathways [35,36], prompted 
us to characterize them in our paradigms. Oxidative stress occurs as a consequence of 
the imbalance between the rate of ROS production and neutralization by specific 
detoxifying proteins, frequently leading cells to death either by apoptosis or necrosis. 
We found an accumulation of ROS at times as early as 30 min after PES treatment. 
Moreover, thiolic antioxidants conferred the highest protection facing PES when 
compared to the other compounds tested (Fig. 3A). To our knowledge, only one report 
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exists about ROS involvement in the lethal mode of action of PES [22]. However, the 
authors show that PES triggers apoptosis rather than necrosis. Two main issues need 
to be taken into account in their work: the delayed kinetics of ROS accumulation, 
starting at 4 h of treatment, and the non-tumor origin of their cellular model, which is 
based on rainbow trout, gill-derived, cells. In addition we report a pharmacological 
cooperation between PES and BSO that translates into an increased ROS content and 
a greater cytotoxicity. This cooperation reinforces our conclusion about PES-mediated 
ROS generation but, in addition, it raises strategic implications for cancer therapy. In our 
laboratory, we have observed BSO to be minimally toxic for cells unless subjected to 
other simultaneous stresses. This is consistent with BSO being well tolerated by 
humans in clinical assays [37,38]. The association of BSO and anticancer drugs in not 
new, it has been described, for example, with retinoids in neuroblastoma [39], 
melphalan or cisplatin in ovarian  cancer [40,41],  vitamin D in breast cancer [42], or 
azathioprine in colon and hepatic carcinoma [43]. We have no knowledge about PES 
toxicity in humans. However, BSO combined to PES will probably allow the reduction of 
PES doses, not decreasing its efficacy and minimizing its nonspecific effects. 
Multiple lines of evidence exist on the mutual regulation of p53 and ROS. For 
instance, DNA damage by ROS triggers an alarm response with p53 as the central 
player. Moreover, ROS activate phosphorylation cascades trough p38α MAPK and ERK 
ending up in p53 stabilization [44]. Finally, oxidation of cysteine residues in p53 modifies 
its DNA binding activity and the transcription of specific genes [45]. Our data evidenced 
ROS inhibition attenuates p53 increase in response to PES, thus positioning ROS 
upstream of p53 up-regulation. On the other hand, p53 can promote ROS generation by 
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transcriptionally inducing enzymes, such as quinone oxidoreductase or proline oxidase, 
or pro-oxidant genes, such as BAX, PUMA and p66Shc [45]. Similarly, p53-mediated 
suppression of antioxidant genes such as manganese superoxide dismutase (MnSOD), 
could finally impinge on the ROS content [45]. Though p53 is known to respond to ROS 
by inducing either anti-oxidant or pro-oxidant genes, it has been suggested that the 
severity of the stimulus could be critical in making this decision [46]. In support of the 
pro-oxidant role of p53, we found that HCT116 p53-/- cells generate a limited amount of 
ROS when compared to HCT116 (Fig. 7B).  
Our results using multiple cell lines are consistent with previous data reporting 
PES elicits a caspase-independent cell death characterized by a prominent cytoplasmic 
vacuolization [2]. The same authors report a null effect of up-regulating the anti-
apoptotic BCL-XL protein on PES-induced cell demise. In the same line, we have found 
that MEF Bax-/-Bak-/- cells remain fully sensitive to PES-triggered cell death. Since 
these cells are fully resistant to apoptosis through the intrinsic pathway [15], these data 
prove that death pathways engaged by PES are clearly unrelated to apoptosis. 
Consistently, in primary effusion lymphoma PES triggers a caspase-independent cell 
death mediated by lysosomal permeabilization [19]. Nonetheless, in other cellular 
models, apoptosis seems to be the main type of cell death caused by PES [20–22]. To 
complete the picture, a simultaneous mixture of both caspase-dependent and 
independent cell death was found in pancreatic cell lines treated with PES [23]. These 
data, which seem to be contradictory, can be explained by differences in the cell death 
behavior, inherent to each cellular model. Alternatively, taking into account our results, 
another plausible explanation would be the different cellular ability to buffer PES-driven 
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oxidative stress. Indeed, it is broadly accepted that ROS have the capability to modulate 
apoptosis. For instance, low concentrations of H2O2 trigger caspase-dependent 
apoptosis while higher amounts elicit necrosis and impair caspase activation [47]. In this 
sense, it is known that direct oxidation of the cysteine from the catalytic center of 
caspases is able to inhibit these proteases [47]. Along the same line, our results prove 
first, that PES is unable to promote the activation of caspases in multiple cell lines (Fig. 
2 A, B and C) and second, that the pan-caspase inhibitor Q-VD-OPh is unable to protect 
cells from PES-driven necrosis (Fig. 3A).  
Pioneer studies cataloged cell death processes into three main morphological 
categories: apoptosis, autophagic cell death and necrosis. Through time, the need of a 
more precise definition has become evident and the evaluation of new biochemical 
parameters has implemented the original classification [48]. Similarly, pharmacological 
strategies have been set up to distinguish between these processes of cell death. 3-MA 
and Spautin-1 are compounds known for its activity suppressing autophagy [49–51]. 
Our data showed neither 3-MA nor Spautin-1 were able to block cell death in response 
to PES. The absence of protection suggests the induction of autophagy is not involved 
in the mechanism of death by PES. Additionally, it is known that PES impairs the 
autophagy-lysosome systems, resulting in a accumulation of autophagic vacuoles and 
generation of proteotoxic stress [2,19]. Furthermore, combination of PES with 3-MA or 
Spautin-1 enhances cytotoxicity in SH-SY5Y cells, thus suggesting autophagy could be 
playing a protective role, instead. MEFs Atg5-/- are unable to perform the classical 
autophagy pathway [52] and thus, they are a valuable tool to study the involvement of 
autophagy under different settings. Experiments from our laboratory have revealed that 
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MEFs Atg5-/- display a greater susceptibility to PES-driven death (data not shown). We 
believe these results are consistent with the role of autophagy attenuating proteotoxicity 
[53] and thus, diminishing the proteotoxic stress inflicted by PES. 
Necrosis is morphologically characterized by rounding of the cell, a gain in cell volume 
(also known as oncosis), organelle swelling, lack of internucleosomal DNA 
fragmentation, and plasma membrane rupture [54]. Despite its early association to 
accidental forms of cell death, new data link it to regulated forms of cell demise, 
otherwise known as “programmed necrosis”. In this sense, necroptosis is currently the 
best characterized form of programmed necrosis [55]. In our experiments, the absence 
of protective effects of the combination of Necrostatin-1 and PES, indicates PES 
triggers a non-necroptotic necrosis. While the physiological relevance of alternative 
forms of cell death remains under study, there is no doubt about the spontaneous 
appearance of mechanisms to elude them. These mechanisms are clearly linked to 
chemoresistance in cancer. For instance, overexpression of PDIA6, a protein disulfide 
isomerase, is one of the mechanisms accountable for the increased chemoresistance of 
lung adenocarcinoma to cisplatin-induced necroptosis [56]. Similarly, ROS-induced 
miR-21 promotes apoptotic resistance of vascular smooth muscle cells to oxidative 
stress [57]. Infectious myocarditis presents both forms of cell death: apoptosis and 
necrosis. Forced expression of miR-21 reduces apoptotic myocarditis through the down-
regulation of programmed cell death 4 (PDCD4) messenger [58]. Nevertheless, the 
overexpression of the same microRNA has no impact reducing necrotic-type 
myocarditis [58]. In conclusion, we believe that inducers of non-canonical forms of 
programmed necrosis harbor a great potential for new-line pharmacological therapies.  
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FIGURE LEGENDS 
FIGURE 1. PES-driven cell death is concentration and time dependent. A. The cell lines 
indicated in the graph were treated for 24 h with increasing concentrations of PES. Cell 
viability was calculated by the MTS reduction assay. B. SH-SY5Y and C, HCT116 WT 
cells were exposed to the indicated concentrations of PES. Cell death by PI staining 
was quantified over time.  Each value in the graphical representation is the average ± 
S.D. of at least 3 independent experiments with 3 independent measurements per 
experiment. 
 
FIGURE 2. PES triggers caspase-independent non-apoptotic cell death. A. SH-SY5Y 
cells were challenged with 12.5 µM PES or STS 250 nM and the time course of caspase 
activation (DEVDase activity) was determined. Activity is measured in arbitrary 
fluorescence units (a.f.u). Each point is the average ± S.D. of 6 independent 
measurements. The plotted profile is representative of 3 independent experiments. 
***P<0.001 (Student’s t-test referred to time 0). B. HCT116 cells were treated with 25 
µM PES or 250 nM STS and processed as in A. C. U87MG, HeLa, 293HEK and HL-60 
were subjected for 12 h to 20, 25, 50 or 15 µM PES respectively. In parallel, cells were 
exposed to vehicle (V) or STS 250 nM for 12 h. Caspase activation (DEVDase activity) 
was quantified as above. D. MEF defective in BAX and BAK proteins and their WT 
controls were treated for 24 h with 30 µM PES or, alternatively, with 1 µM STS. Cell 
viability was measured by the MTS reduction assay. Bar value is the mean ± S.D. of at 
least 3 independent determinations in 3 independent experiments. 
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FIGURE 3. PES triggers a non-necroptotic, necrotic type of cell death. A. After a 
preincubation of 3 h with 10 µM QVD-OPh (QVD), 25 µM Necrostatin-1 (Nec), 10 mM 3-
MA (3-MA) or 10 µM Spautin-1 (Spautin), PES was added for 12 h at a concentration of 
25 µM for HCT116 and 12.5 µM for SH-SY5Y cells. A control of vehicle-treated cells 
was included (C). Cell survival was quantified by Alamar blue. When a combined 
treatment was performed (PES + inhibitor), Alamar blue values were referred to the 
ones of the cells treated with the inhibitor alone. Bar value is the mean± S.D. of at least 
3 independent experiments with three independent measurements per experiment. **P< 
0.005 (Student’s t-test referred to PES-treated control). B. Transmission electron 
microscopy of HCT116 in untreated conditions. C. HCT116 cells treated for 48h with 25 
µM PES, displaying an early necrotic phenotype. D. HCT116 treated as in C, showing a 
more advanced necrotic phenotype. Arrows indicate areas of discontinued plasmatic 
membrane. E. Control SH-SY5Y cells untreated. F.  SH-SY5Y cells treated with 12.5 
µM PES for 12h. Arrowhead indicates the multilamellar autophagosome structure 
shown at higher resolution in the inset. Nu: Nuclear chromatin. G: Golgi apparatus. m: 
mitochondria. Black asterisks: Vacuoles. White asterisks: Dilated mitochondria with 
disrupted cristae. 
 
FIGURE 4. ROS are pivotal elements in necrosis by PES. A. HCT116 cells were treated 
with 25 µM PES or DMSO (Vehicle) for the times indicated in the x-axis. Quantification 
of ROS was performed as described in the methods section and expressed as arbitrary 
fluorescence units (a.f.u) generated by DCF. B. SH-SY5Y cells were pre-incubated for 1 
h with 1.25 mM NAC or 500 µM DTT before adding 12.5 µM PES or DMSO (Vehicle) for 
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an additional 24 h period. Cell death was measured by flow cytometry and the count of 
PI stained cells. C. HCT116 cells were treated with 25 µM PES for 48 h and analyzed 
as reported for SH-SY5Y in B. ***P<0.001 (Student’s t-test referred to PES-treated 
control). D. HCT116 and SH-SY5Y cells were either pre-incubated with BSO or left 
untreated. After a 3 h pre-incubation, PES was added at 6.25 µM for an extra 8 h 
period. ROS fluorescent signal was referred to the one of the DMSO (Vehicle) treated 
cells. ***P<0.001 (Student’s t-test referred to PES-treated control). E. Cell lines 
indicated in the x-axis were pre-incubated for 3 h with 50 µM BSO or left untreated. PES 
was then added at the concentrations reported in the x-axis. Cell survival was 
determined by the Alamar blue procedure. Bar value is the average ± S.D. of at least 3 
independent experiments with 3 independent measurements. ***P<0.001 (Student’s t-
test referred to PES-treated control). 
 
 
FIGURE 5. p53 participates in PES-driven necrosis. A. HCT116 WT and HCT116 p53-/- 
cells were challenged with the indicated concentrations of PES for a period of 24 h. Cell 
survival was assessed by MTS reduction. Plots represent the average ± S.D. of at least 
3 independent experiments with 3 independent determinations. B. HCT116 and 
HCT116 p53-/- were treated for 48 h with 25 µM PES. Cell death was determined by 
flow cytometry count of PI stained cells. Bar value equals mean ± S.D. of at least 3 
independent experiments with 3 independent measurements. C. HCT116 p53-/- cells 
transfected with a plasmid carrying a functional p53 (p53) or empty (Vector) were 
subjected to PES treatment. Cell survival by MTS reduction was evaluated after 24 h. 
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Results are the average ± S.D. of at least 3 independent experiments with 3 
independent determinations. **P< 0.005 ; ***P<0.001 (Student’s t-test). 
 
FIGURE 6. p53 is predominantly located at the chromatin-bound subfractions in 
response to PES. A. SH-SY5Y cells were treated for 6 h with PES 12.5 µM (P), 
Staurosporine 1 µM (STS) or left untreated (C).  Cells were next subjected to 
subfractionated extractions as reported in the text.  Cytosolic (Cyt), nucleoplasmic (N1) 
and chromatin-enriched (N2) extracts were obtained. These extracts were analyzed by 
Western-blot with p53, LDH and PTBP1 antibodies as stated in the figure. NB refers to 
the membrane stained with naphtol blue to assess an even loading of protein per 
fraction.  Next to the image the quantitation of p53 content in N1 and N2 fractions 
expressed as “normalized signal intensity” to the p53 in left untreated extracts (C) and 
performed as described in the methods section. Results are the average ± S.D. of 2 
independent experiments.  B. SH-SY5Y cells were treated with PES 12.5 µM for the 
indicated times. Total extracts were obtained and p53 and p21 content was detected by 
Western-blot. GAPDH was used to control protein loading. The quantification of p53 and 
p21 content referred to GAPDH is indicated below each panel. Image is the result of 
one representative experiment out of two C. HCT116 cells were infected with a virus 
carrying a shRNA against p53 or an empty one. Cell survival was assessed by MTS and 
referred to the values of vehicle treated cells. Results are the average ± S.D. of at least 
3 independent experiments with 3 independent measurements per experiment. D. SH-
SY5Y cells were processed and viability assessed as stated before in C for HCT116. 
**P< 0.005 ; ***P<0.001 (Student’s t-test). 
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FIGURE 7. ROS and p53 mutually regulates each other in response to PES. A. SH-
SY5Y cells were pre-incubated with 500 µM DTT or left untreated. Then exposed to 
12.5 µM PES or vehicle for 6 h. Total protein extracts were performed and analyzed by 
Western-blot with p53 and GAPDH antibodies. GAPDH was used to control the protein 
load. Below, quantitation of the p53 expressed as “normalized signal intensity” to the 
p53 in left untreated extracts and performed as described in the methods section. 
Results are the average ± S.D. of 2 independent experiments. B. HCT116 and HCT116 
p53-/- isogenic cells were treated with 25 µM PES for 6 h. Quantification of ROS was 
referred to a control with DMSO (vehicle). Quantification procedure is described in the 
methods section and expressed as arbitrary fluorescence units (a.f.u) generated by 
DCF. *P<0.01; (Student’s t-test). 
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